/BBIO
BridgeBio Pharma, Inc.
BBIO • NASDAQBBIO • NASDAQ • Healthcare
$69.35+2.01%+1.37
$69.35+2.01%(+1.37)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
73Low Risk
Momentum
67Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
94.4%▼3.9pp
Revenue after COGS
Operating
-113.3%▲153.9pp
After operating expenses
Net
-145.3%▲96.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-20.7
Price vs earnings
EV/EBITDA
-25.6
Enterprise value
FCF Yield
-3.0%
Cash generation
Earnings Yield
-4.8%
Inverse of P/E
Capital Efficiency
-59
GoAI Quality ScorePoor
⚠High Leverage Risk
Large ROE-ROA gap with weak interest coverage suggests the high returns are fueled by excessive debt rather than operational efficiency.
ROEReturn on Equity
35.1%Strong
ROAReturn on Assets
-77.9%Weak
ROICReturn on Invested Capital
-108.5%Weak
Financial Health
Current RatioHealthy
2.62
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-3.21x
Debt repayment capacity (<3x)
Income QualityFair
0.62
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $502.08M | $221.90M | $9.30M | $77.65M | $69.72M |
| Gross Profit | $473.81M | $218.02M | $6.86M | $74.21M | $66.60M |
| Gross Margin | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% |
| Operating Income | -$569.09M | -$592.97M | -$607.37M | -$512.20M | -$576.63M |
| Net Income | -$729.31M | -$535.76M | -$643.20M | -$481.18M | -$562.54M |
| Net Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% |
| EPS | -$3.79 | -$2.88 | -$3.95 | -$3.35 | -$3.90 |
Average Price Target
$99.85▲ 44.0% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for BridgeBio Pharma, Inc., the average price target is $99.85, with a high forecast of $157.00 and a low forecast of $83.00. The average price target represents a 44.0% increase from the current price of $69.35.
Highest
$157.00
Average
$99.85
Lowest
$83.00
Rating Distribution
Strong Buy
0
0%
Buy
25
96%
Hold
1
4%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
JP Morgan● Maintain
Overweight
2026-03-10Evercore ISI Group● Maintain
Outperform
2026-02-25Truist Securities● Maintain
Buy
2026-02-25Morgan Stanley● Maintain
Overweight
2026-02-25Oppenheimer● Maintain
Outperform
2026-02-25HC Wainwright & Co.● Maintain
Buy
2026-02-17Oppenheimer● Maintain
Outperform
2026-02-13Wells Fargo● Maintain
Overweight
2026-02-13Wells Fargo● Maintain
Overweight
2026-01-20Truist Securities● Maintain
Buy
2026-01-08Earnings History & Surprises
BEAT RATE
33%
Last 18 quarters
AVG SURPRISE
-1.9%
EPS vs Estimate
BEATS / MISSES
6/12
Last 18 quarters
LATEST EPS
$-1.00
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-40.2%
$-1.00 vs $-0.71
Q4 '25
-8.0%
$-0.95 vs $-0.88
Q3 '25
-14.5%
$-0.95 vs $-0.83
Q2 '25
+12.0%
$-0.88 vs $-1.00
Q1 '25
-20.2%
$-1.31 vs $-1.09
Q4 '24
+16.5%
$-0.86 vs $-1.03
Q3 '24
+6.4%
$-1.02 vs $-1.09
Q2 '24
+87.5%
$-0.05 vs $-0.40
Q1 '24
-1.1%
$-0.96 vs $-0.95
Q4 '23
-25.6%
$-1.08 vs $-0.86
Q3 '23
-14.0%
$-0.98 vs $-0.86
Q2 '23
-9.5%
$-0.92 vs $-0.84
No investor questions available.
Latest News
No news available